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ABSTRACT 
 
Oral drug delivery is the most widely utilized route of administration among all the routes that have been 
explored for systemic delivery of drugs via pharmaceutical products of different dosage form. Oral route is 
considered most natural, uncomplicated, convenient and safe due to its ease of administration, patient ac-
ceptance and cost-effective manufacturing process. Gastroretentive drug delivery system was developed in 
pharmacy field and drug retention for a prolonged time has been achieved. The goal of this study was to 
formulate and in-vitro evaluate Ciprofloxacin HCl controlled release matrix floating tablets. Ciprofloxacin 
HCl floating matrix tablets were prepared by wet granulation method using two polymers such as HPMC 
K100M (hydrophilic polymer) and HPMC K15M. All the Evaluation parameters were within the acceptable 
limits. FTIR spectral analysis showed that there was no interaction between the drug and polymers. In-vitro 
dissolution study was carried out using USP dissolution test apparatus (paddle type) at 50 rpm. The test 
was carried out at 37 ± 0.5 0C in 900ml of the 0.1 N HCl buffer as the medium for eight hours. HPMC K100M 
shows a prolonged release when compared to HPMC K15M. These findings indicated that HPMC K100M can 
be used to develop novel gastroretentive controlled release drug delivery systems with the double ad-
vantage of controlled drug release at GIT pH. On comparing the major criteria in evaluation such as prefor-
mulation and in vitro drug release characteristics, the formulation F8 was selected as the best formulation, 
as it showed the drug content as 99±0.4% and swelling index ratio was 107.14, and in-vitro drug released 
61.31±0.65% up to 8 hours. Results indicated that controlled Ciprofloxacin HCl release was directly propor-
tional to the concentration of HPMC K100M and the release of drug followed non-Fickian diffusion. Based 
on all the above evaluation parameters it was concluded that the formulation batch F8 was found to be best 
formulation among the formulations F1 to F8 were prepared. 
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INTRODUCTION 
Oral drug delivery is the most widely utilized route of 
administration among all the routes that have been 
explored for systemic delivery of drugs via pharma-
ceutical products of different dosage form. Oral route 
is considered most natural, uncomplicated, conven-
ient and safe due to its ease of administration, patient 
acceptance and cost-effective manufacturing process 
[1]. 
Pharmaceutical products designed for oral delivery 
are mainly conventional drug delivery systems, 
which are designed for immediate release of drug for 
rapid absorption. These immediate release dosage 
forms have some limitations such as [2, 3]. 
Sustained release (SR) - gastroretentive dosage forms 
(GRDF) enable prolonged and continuous input of the 
drug to stomach and upper parts of the gastrointesti-
nal (GI) tract. These systems are designed to be re-
tained in the stomach for longer period of time and 
hence significantly prolong the gastric residence time 
of drugs. Therefore, different approaches have been 
proposed to retain the dosage form in the stomach in-
cluding bioadhesive systems, swelling and expanding 
systems, floating systems and delayed gastric empty-
ing devices [4, 5, 6]. 
Among these, the floating dosage form has been used 
most commonly. This technology is suitable for drugs 
with an absorption window in the stomach or in the 
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upper part of the small intestine, drugs acting locally 
in the stomach, and for drugs that are poorly soluble 
or unstable in the intestinal fluid. The floating sys-
tems include single, multiple and raft forming sys-
tems. The principle of these systems offers a simple 
and practical approach to achieve increased gastric 
residence time for the dosage form and sustained 
drug release [7, 8, 9]. 
The present investigation is concerned about the de-
velopment of effervescent floating drug delivery sys-
tems that generate CO2, thus reduces the density of 
the system in the stomach for prolonged period of 
time and releases the drug slowly at desired rate. For-
mulation of extended release effervescent floating 
tablets of Ciprofloxacin HCl improves patient compli-
ance and minimizes the dose related side effects. 
Therefore, this study aims at formulating once‐a day 
floating hydrophilic matrix tablets using hydroxypro-
pyl methylcellulose (HPMC K15 and K100) as a re-
lease rate modifying polymer, NaHCO3 and talc were 
used as floating aid and release modifier. 
In order to optimize the therapy research efforts have 
been focused on the development of oral sustained 
release (SR) preparations as well as controlled re-
lease gastro retentive dosage forms. A conventional 
oral SR formulation releases most of the drug content 
at colon, thus requiring that the drug will be absorbed 
from colon. 
The above drawbacks provide a rationale for devel-
oping Ciprofloxacin Hydrochloride as a gastro reten-
tive dosage form, which is retained in the stomach 
and produces a constant input of drug to the absorp-
tion site. This improves the bioavailability of the drug, 
reduces frequency of dosing, thus minimizes side ef-
fects and enhances patient compliance. The present 
study a systematic approach for the development of 
intra gastric Buoyant tablets of Ciprofloxacin Hydro-
chloride with a view to enhance its oral bioavailabil-
ity and efficacy. 
MATERIALS AND METHOD 
Ciprofloxacin Hydrochloride and all the polymers 
were procured from SD Fine Chemicals Ltd., Mumbai. 
All other chemicals and ingredients for study were of 
analytical grade. 
Preparation 
Effervescent floating tablets containing drug (50mg) 
were prepared by wet granulation technique (slug-
ging) using varying concentrations of polymers i.e. 
hydroxy propylmethyl cellulose HPMC K15, HPMC 
K100 and sodium bicarbonate as effervescent compo-
nent. All the ingredients were accurately weighed and 
passed through different mesh sieves accordingly. 
Then, except magnesium stearate and talc all other 
ingredients were blended uniformly in polyethylene 
bag for 5‐6 min. Slugging the powder blend and sifted 
through sieve no. #22. Granules were lubricated with 
magnesium stearate and talc (1-2%) for additional 
3min., compressed in to tablets using a 16 station ro-
tary tablet machine (Cadmach, Ahmedabad, India.) 
using 8mm standard flat face punch, compression 
force was adjusted to obtain tablets with hardness in 
range of 5.1 ± 0.51‐ 5.8 ± 0.23 kp. The tablet weights 
were 300±2 mg with average diameter of 9.0±0.2 
mm. 
Evaluation of granules 
Pre-compression parameters of granules 
The flow properties of granules (before compression) 
were characterized in terms of angle of repose, 
tapped density, bulk density and Carr’s index [10, 11]. 
Evaluation of tablets 
All prepared matrix tablets were evaluated for its uni-
formity of weight, hardness, friability and thickness 
according to official methods [12]. The weight varia-
tion was determined by taking 20 tablets individu-
ally, calculating the average weight, and comparing 
the individual tablet weights to average of tablet. Tab-
let hardness was determined for 10 tablets using a 
Monsanto tablet hardness tester (MHT‐20, Campbell 
Electronics, Mumbai, India). Friability was deter-
mined by testing 10 tablets in a friability tester (FTA‐
20, Campbell Electronics) for 4 minutes at 25 rpm. 
Acceptance criteria are not more than 1 % of their 
weight. 
In Vitro drug release study 
The release rate of the drug from floating tablets was 
determined using USP testing apparatus II (Paddle 
Type DISSO 2000). The dissolution test was per-
formed using 900ml of 0.1N HCl at 37±0.5oC and 50 
rpm. 5ml of aliquots were withdrawn at specific time 
intervals and the level of the dissolution media was 
maintained by replacing the same which was already 
maintained at sink conditions. The samples were fil-
tered through a 0.45 μm membrane filter. Absorb-
ance of these samples were taken at 277nm using UV 
visible spectrophotometer (Shimadzu UV 1700) 
against 0.1N HCl as blank. Cumulative percent drug 
release was calculated. 
Assay of tablets 
The drug content in each formulation was deter-
mined by triturating 10 tablets and a quantity of pow-
der equivalent to the mass of one tablet was extracted 
with pH 1.2 buffer and the solution was filtered 
through 0.45 μ membranes. The absorbance was 
measured at 277nm after suitable dilution. 
Floating lag time and total floating time 
The time between the introduction of a floating tablet 
of the drug in to the medium and its buoyancy to the 
upper one third of the dissolution vessel was meas-
ured as floating lag time which is a part of dissolution 
studies. The time for which FDDS constantly float on 
the water surface is total floating time. It is performed 
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by visual observations during the dissolution studies 
[13, 14]. 
Kinetics of drug release 
A gel layer is formed around the tablet core when the 
tablet containing a polymeric matrix comes in contact 
with water, which governs the drug release. Drug re-
lease from HPMC matrix tablets is controlled by dif-
fusion through the gel layer in case of water soluble 
drug or by erosion of the outer polymer chains for 
water insoluble drugs. Hence, the kinetics of swelling 
is important because the gel barrier is formed with 
water penetration. The drug release rate kinetics was 
calculated for zero order, first order and Higuchi 
models [15, 16, 17]. 
Mechanism of drug release 
The mechanism of drug release was determined by 
fitting the drug release data of drug release to 
Korsmeyer et al’s equation and graphs were plotted 
as log cumulative percentage of drug release vs. log 
time and the exponent n was calculated through the 
slope of the straight line and finding the R2 values of 
the release profile corresponding to each model 
Mt/M∞ = atn, Where Mt/M∞ is the fractional solute 
release, t is the release time, a is constant incorporat-
ing structural and geometrical characteristics of the 
drug dosage form and n is the release exponent indic-
ative of drug release mechanism and function of time, 
t. For cylindrical matrix tablets, if the exponent n = 
0.45, then the drug release mechanism is Fickian dif-
fusion, and if 0.45 < n <0.89, then it is non‐Fickian or 
anomalous diffusion. An exponent’s value of 0.89 is 
indicative of case‐II Transport or typical Zero order 
release [17]. 
Stability studies 
The stability studies were carried out on optimized 
formulation i.e. F8. The formulations were stored at 
40oC/ 75 % RH for three months to assess their long 
term stability. Samples were withdrawn after 1, 2 & 3 
months and retested for physical properties, drug 
content, floating lag time and in vitro drug release. 
RESULTS AND DISCUSSION 
The present study was aimed to prepare and evaluate 
effervescent floating matrix tablets of Ciprofloxacin 
Hydrochloride with HPMC K15 and HPMC K100 as 
polymer using wet granulation technique. HPMC was 
chosen because it is widely used as a low density hy-
drocolloid system upon contact with water a hydro-
gel layer would be formed to act as a gel boundary for 
the delivery system, but it would fail to retard the re-
lease of drug through the matrix because of its solu-
bility in intestinal pH. Magnesium stearate acts as 
buoyancy increasing agent and also improves the gel-
ling property of polymer. Magnesium stearate was 
used in combination with HPMC to slow the drug re-
lease. 
The granules prepared for compression of floating 
tablet were evaluated for their flow properties (Table 
2). Angle of repose (ø) was in the range of 23.73 ± 1.2 
to 26.22. Bulk density ranged between 0.345 ±0.03 to 
0.435 ± 0.04 gm/cm3. Tapped density ranged be-
tween 0.372 ± 0.04 to 0.480 ± 0.02 gm/cm3. Carr’s In‐
dex was found to be 21.88 ± 0.18 to 23.86 ± 0.32. 
These values indicate that the prepared granules ex-
hibited good flow properties. 
The average weight and hardness of the tablets were 
found in the range of 283 ± 0.6 to 320 ± 0.9mg and 7.2 
± 0.2 ‐ 8.0 ± 0.3kg/cm2 respectively as shown in ta-
ble3. The friability was below 1% for all the formula-
tions, which is an indication of good mechanical re-
sistance of the tablet. 
On immersion in 0.1 N HCl, pH 1.2 solution at 37 ± 
0.50C all effervescent floating tablets floats immedi-
ately and remain buoyant up to 8hr without disinte-
gration. Sodium bicarbonate was added as a gas‐gen‐
erating agent. Sodium bicarbonate induced carbon di-
oxide generation in presence of dissolution medium 
(0.1 N hydrochloric acid). It was observed that the gas 
generated is trapped and protected within the gel, 
formed by hydration of polymer (HPMC K 100M), 
thus decreasing the density of the tablet below 1 and 
tablet becomes buoyant. The tablet swelled radially 
and axially during in vitro buoyancy studies. The cu-
mulative percent drug release was found to be 61.31 
± 0.65% at 8hr. Among all the formulations F8 was 
found to be the optimized one in terms of floating lag 
time and drug release at the end of 8hr as shown by 
results in table 3. The dissolution profiles of all the 
formulations are shown in (Figure 1, Figure 2, Figure 
3 and Figure 4). 
The assays of tablets of all the formulations were 
found within the range as per the requirement of 
pharmacopoeia. When the concentration of polymer 
was increased, the lag time was increased but total 
drug release was decreased. The data clearly indicate 
the drug release can be effectively controlled by var-
ying the polymer and its ratio. Incorporated sodium 
bicarbonate into the HPMC matrix could increase the 
drug release rate. The increase in the quantity of so-
dium bicarbonate decreases the lag time but in-
creases the drug release. As magnesium stearate is 
hydrophobic in nature and when it was increased ex-
tra granularly then floating lag time was increased 
slightly but no effect on initial drug release from the 
matrix tablets. 
The data obtained from in-vitro dissolution studies 
were fitted in different models viz. Zero order, First 
order, Higuchi and Korsmeyer Peppa’s equation 
(shown in Table 4). The Higuchi plots were found to 
be followed as indicated by their high regression val-
ues (r2 = 0.929 to 0.996). To confirm the exact mech-
anism of drug release from these tablets, the data was 
fitted to Higuchi and Korsmeyer Peppa’s equation. 
The formulation F8 with HPMC K 100 M (20%) shows 
maximum release of 61.31±0.65 % at a time period of  
8 hours in a controlled manner. The in-vitro release 
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plot has shown drug release followed by Higuchi plot,  
which was also confirmed from the regression value 
in Table 4. From the regression and slope value of Hi-
guchi’s (0.986) and Peppa’s (n = 0.994) plot respec‐
tively, the drug release was confirmed to followed by 
diffusion mediated non‐Fickian transport mecha‐
nism. 
The optimized F8 formulation was subjected to sta-
bility studies for 3 months. At the interval of 30 days 
the tablets were withdrawn and evaluated for hard-
ness, thickness, weight variation, friability. All the pa-
rameters have not shown much variation when com-
pared to the initial data. The in-vitro dissolution was 
also carried out for specified time intervals. Based on 
the results, we observed that, drug release profiles 
were not affected by exposing to temperature and the 
specified humidity conditions. 
Table 1: Formulation batches of effervescent floating tablets of Ciprofloxacin Hydrochloride 
Ingredients 
Formulation Code 
F1 F2 F3 F4 F5 F6 F7 F8 
Ciprofloxacin HCl 50 50 50 50 50 50 50 50 
HPMC K15M 50 100 150 200 ------- ------ ------ ----- 
HPMC K100M ----- ------ ------ ------ 50 100 150 200 
NaHCO3 45 45 45 45 45 45 45 45 
Magnesium 
Stearate 
3 3 3 2.5 3 3 3 2.5 
Microcrystalline cellulose 154 99 49 ___ 154 99 49 ___ 
Talc 3 3 3 2.5 3 3 3 2.5 
*All the quantities are in mg 
Table 2: Granule properties of formulation F1 to F8 of Ciprofloxacin Hydrochloride matrix tablets 
Parameters 
Formulation Code 
F1 F2 F3 F4 F5 F6 F7 F8 
Angle of Repose (ø) 
25.16 
±1.2 
25.35 
±1.4 
26.12 
±1.6 
24.43 
±1.3 
23.73 
±1.2 
26.22 
±1.6 
24.18 
±1.0 
25.30 
±1.4 
Bulk Density (gm/cm3) 
0.435 
±0.04 
0.358 
±0.06 
0.420 
±0.02 
0.376 
±0.02 
0.345 
±0.03 
0.425 
±0.02 
0.409 
±0.03 
0.369 
±0.02 
Tapped Density (gm/cm3) 
0.476 
±0.03 
0.427 
±0.01 
0.386 
±0.03 
0.462 
±0.02 
0.418 
±0.03 
0.385 
±0.02 
0.480 
±0.02 
0.372 
±0.04 
Carr’s Index (%) 
22.26 
±0.14 
21.88 
±0.18 
22.46 
±0.40 
23.86 
±0.32 
22.82 
±0.42 
23.81 
±0.45 
22.92 
±0.32 
23.76 
±0.18 
*Each reading is an average of three determinations (Avg.± S.D) 
Table 3: Different properties of tablets of batch F1 to F8 
Formula-
tion 
No. 
Avg. Weight 
(Mean ± 
S.D) 
(n=20) 
Hard-
ness 
(kg/cm2) 
(n=3) 
Friability 
(Mean±S.D) 
(n=20) 
% Drug con-
tent 
(mg) 
Buoy-
ancy 
lag time 
(min) 
Total float-
ing 
Time (hrs) 
Matrix 
integ-
rity 
F1 283±0.6 7.2±0.2 0.546 97±0.7 4 8 + 
F2 320±0.9 7.5±0.2 0.612 99±0.5 10 8 + 
F3 297±0.3 8.0±0.3 0.827 100±0.6 8 8 + 
F4 291±0.4 7.6±0.2 0.611 99±0.6 6.1 8 + 
F5 286±0.8 7.6±0.2 0.625 99±0.6 5.0 8 + 
F6 304±0.8 7.3±0.4 0.655 98±0.5 3 8 + 
F7 294±0.4 8.0±0.2 0.711 100±0.3 8.5 8 + 
F8 292±0.4 7.7±0.5 0.702 99±0.4 8.6 8 + 
*Each reading is an average of three determinations (Avg.± S.D) 
Table 4: Release kinetic parameters of floating tablets of Formulation F1 to F8 
Formulation Code Zero order First order Higuchi’s Korsmeyer Peppa’s 
F1 0.976 0.870 0.929 0.934 
F2 0.975 0.915 0.954 0.971 
F3 0.937 0.940 0.996 0.994 
F4 0.971 0.990 0.994 0.995 
F5 0.983 0.923 0.957 0.966 
F6 0.992 0.954 0.966 0.975 
F7 0.975 0.955 0.970 0.985 
F8 0.979 0.981 0.986 0.994 
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Figure 1: Dissolution profile of Ciprofloxacin HCl float-
ing tablets (F1, F2) formulations. 
 
Figure 2: Dissolution profile of Ciprofloxacin HCl float-
ing tablets (F3, F4) formulations.  
 
Figure 3: Dissolution profile of Ciprofloxacin HCl float-
ing tablets (F5, F6) formulations. 
 
Figure 4: Dissolution profile of Ciprofloxacin HCl float-
ing tablets (F7, F8) formulations 
CONCLUSION 
Based on the results and discussion, we can con-
cluded that controlled release tablets of Ciprofloxacin 
HCl were prepared successfully by wet granulation 
using different concentration of polymers like HPMC-
K15, HPMC-K100 and other excipients such as mag-
nesium stearate as lubricant, talc as glidants and mi-
crocrystalline cellulose as diluent were found to be 
good without chipping, capping and sticking. There 
are various approaches to increase the gastric reten-
tion time of dosage form and floating system is one of 
the approaches for delivery of drugs which are ab-
sorbed from stomach and upper small intestine. 
Ciprofloxacin HCl has high solubility in stomach pH 
and is formulated as effervescent floating drug deliv-
ery system. For antibiotic therapy, the drug has to ad-
minister for long period of time and due to this more 
drug will be accumulated in the body, which ulti-
mately increases the side effects. This targeted deliv-
ery of the drug through FDDS reduces the dose, dura-
tion of therapy and also the side effects. 
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